Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
UGP2 CRISPR/Cas9 KO Plasmid (h): sc-408778
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UGP2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UGP2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: UGP2 Antibody (B-3): sc-377089
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UGP2 CRISPR/Cas9 KO Plasmid (h) | sc-408778 | 20 µg | $397.00 |
Overview
UGP2 encodes UDP-glucose pyrophosphorylase 2, a cytosolic enzyme that catalyzes the reversible formation of UDP-glucose from glucose-1-phosphate and UTP, supplying a central activated sugar nucleotide for biosynthesis. UDP-glucose supports glycogen metabolism and contributes to glycosylation pathways by providing precursors for glycoconjugate and glycolipid production, influencing protein trafficking and cell–cell interactions. Through its role in carbohydrate flux and glycan homeostasis, UGP2 is often examined in contexts of metabolic rewiring, ER/Golgi processing, and stress adaptation. Altered UDP-glucose availability and glycosylation patterns are broadly relevant to mechanisms implicated across metabolic and proliferative disorders, motivating functional studies of UGP2 in human cells.
UGP2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UGP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UGP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UGP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UGP2 protein expression.
This CRISPR knockout system enables efficient generation of UGP2-deficient cell models for investigation of UGP2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting UGP2 exon(s) critical for UGP2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple UGP2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by UGP2 CRISPR/Cas9 KO Plasmid (h) and UGP2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the UGP2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by UGP2 HDR Plasmid (h) and UGP2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by UGP2 homology arms to support homology-directed repair at defined UGP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.